BRAF and colorectal carcinoma: In addition, LY3009120 has been broadly applied in tumor cells or colorectal carcinoma xenograft models harboring oncogenic RAS or BRAF mutations and Vemurafenib-resistant melanoma cells as well as tumor cells with oncogenic BRAF deletions [19,20,21,22,23,24,25].